Navigation Links
Amerigen Pharmaceuticals Limited today announced it had entered into a collaboration agreement with Forest Laboratories Inc. regarding the development of a number of specialty generic products.
Date:7/31/2013

LYNDHURST, N.J., July 31, 2013 /PRNewswire/ -- Amerigen Pharmaceuticals Limited today announced it had entered into a collaboration agreement with Forest Laboratories Inc. regarding the development of a number of specialty generic products. Under the terms of the agreement, Amerigen will use its formulation expertise to develop a range of complex generic products and will commercialize such products in the United States.  Forest will make undisclosed milestone payments to Amerigen and will receive royalties on US sales of such products.  In addition, Forest will have an option to acquire rights to register and commercialize certain products in Latin America.

John Lowry, Amerigen's President & CEO commented: "This collaboration is a testament to Amerigen's generic formulation and product development capabilities and enables the company to continue its efforts to build a portfolio of differentiated, high value generic pharmaceuticals. It also enables Amerigen to leverage its product development investments into an array of fast growing emerging markets, with the support of a leading international pharmaceutical company."

About Amerigen
Amerigen Pharmaceuticals is a group of companies engaged in all phases of the generic pharmaceutical business, with operations in the US and China. The group is controlled by Amerigen Pharmaceuticals Limited. The US regulatory and commercial activities within the group are conducted by Amerigen Pharmaceuticals Inc., based in Lyndhurst, NJ, USA. The group's Chinese subsidiary, the Suzhou Amerigen Pharmaceutical Company Limited, is located in Suzhou, Jiangsu Province. The group has an active portfolio of products under development, filed, or intended for filing, as ANDA's with the US FDA. Amerigen's focus is orally delivered products that are challenging to develop, require specialized technologies or high containment to manufacture, and present complex regulatory and intellectual property obstacles to bring to market. All Amerigen's products are developed and manufactured by the company or its partners around the world to meet the highest quality standards, including the US FDA.


'/>"/>
SOURCE Amerigen Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Vanda Pharmaceuticals Reports Second Quarter 2013 Results
2. Anthera Pharmaceuticals Reports 2013 Second Quarter Financial Results
3. Isis Pharmaceuticals Earns $2 Million from GSK for the Advancement of ISIS-TTR Rx
4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2013 Second Quarter Financial Results
5. Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802
6. Vanda Pharmaceuticals to Announce Second Quarter 2013 Financial Results on July 31, 2013
7. Webcast Alert: Isis Pharmaceuticals Second Quarter 2013 Financial Results Conference Call
8. Insight Pharmaceuticals Considers Bananacin -- Banana-Flavored Anacin Tablets -- After Worlds Oldest Man Credits Combo As Secret To Long Life
9. Promentis Pharmaceuticals, Inc. Appoints Industry Veteran Chad Beyer, Ph.D., MBA, as President and CEO
10. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2013 Financial Results
11. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Second Quarter 2013 Financial Results On July 31, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Research and Markets has announced the addition of the ... to their offering. ... The ablation device global market is expected to grow at ... Ablation is the minimally invasive therapeutic tissue excision procedure ... tissue removal, to the removal of abnormally conducting cardiac tissue in ...
(Date:3/29/2017)... , March 29, 2017   Dynatronics Corporation ... the appointment of Cynthia L. McHenry ... be responsible for leading Dynatronics manufacturing, distribution, and ... report to Dynatronics, CEO Kelvyn H. Cullimore, ... an extensive search process conducted by the company ...
(Date:3/29/2017)... , March 29, 2017 FinancialBuzz.com News Commentary  ... Data published in a research ... market will reach a value of USD 55.8 billion by 2025. The ... the United States and a more open approach towards cannabis ... , Florida , North Dakota , ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... , ... Hamlin Dental Group, multi-location dental office in North Hollywood , ... are safe and effective options, and can be used alone or in conjunction with ... of care. , Dr. Hamid Reza of Hamlin Dental Group offers other treatments as ...
(Date:3/29/2017)... ... March 29, 2017 , ... Physicians’ Education ... specialized continuing medical education conference for clinicians who manage some of the most ... York. , The program will be led by co- chairs Dr. John ...
(Date:3/29/2017)... , ... March 29, 2017 , ... AvePoint , ... North American office location in Richmond, Virginia, located at the Riverfront Plaza, 901 East ... by Lieutenant Governor of Virginia Ralph S. Northam and Mayor of Richmond Levar M. ...
(Date:3/28/2017)... Boulder, CO (PRWEB) , ... March 28, 2017 ... ... the reasonable assumption that in order to improve teacher quality, the field must ... “blindly swinging from one popular reform to the next” and that decades of ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... For many women, getting birth control isn’t ... deserts , meaning they either don’t have access to a health care facility or a ... and remote regions of the United States or for many who are faced with health ...
Breaking Medicine News(10 mins):